ReviewFrontiers in pharmacology2025
Analgesic effects of bulleyaconitine A: new advances in research from ion channel targets to clinical translation.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain represents a significant global health concern, posing a severe threat to human wellbeing and affecting up to 20% of the adult population. Bulleyaconitine A (BLA), a diterpenoid alkaloid derived from plants of the Aconitum genus with in the Ranunculaceae family, demonstrates remarkable analgesic properties with a low potential for addiction, thus broad clinical application prospects compared to opioids. Extensive research has elucidated multiple pharmacological mechanisms underlying the analgesic effects of BLA, including state-dependent blockade of voltage-gated sodium channels, activation of the κ-opioid receptor pathway in spinal microglia, and anti-inflammatory immunomodulatory effects through inhibition of the NF-κB pathway. These mechanisms have been validated in various pain models, including neuropathic pain, cancer pain, rheumatoid arthritis pain, and visceral pain. However, BLA still faces pharmacokinetic challenges in clinical translation, including a narrow therapeutic window, low bioavailability, and potential neurotoxicity. In recent years, the development of novel drug delivery systems, structural modifications targeting the C-8 and C-14 sites to separate toxicity from efficacy, and advances in artificial intelligence-assisted drug design have provided effective solutions to overcome these limitations. Emerging research suggests that BLA has potential new indications in areas such as visceral hypersensitivity, irritable bowel syndrome, and pain-related anxiety disorders. This article provides a comprehensive review of the ion channel targets, central and peripheral mechanisms of action, pharmacokinetic characteristics, innovative drug delivery strategies, structural optimization pathways, and current clinical application of BLA. It aims to offer valuable references for the further development and rational clinical application of BLA as a non-opioid analgesic with multi-target therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.